Skip to main content

A Phase 1/2 Study Evaluating Brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Seattle Genetics, Inc

Start Date

February 22, 2016

End Date

June 27, 2019
 

Administered By

Duke Cancer Institute

Awarded By

Seattle Genetics, Inc

Start Date

February 22, 2016

End Date

June 27, 2019